Kymera Therapeutics (KYMR) Accumulated Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Accumulated Expenses for 8 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 70.92% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (down 70.92% YoY), while the FY2025 annual figure was $42.3 million, up 21.24% from the prior year.
• Accumulated Expenses slipped to $6.7 million in Q1 2026 per KYMR's latest filing, from $42.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $42.3 million in Q4 2025 and bottomed at $3.6 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $19.2 million across 5 years, with a median of $22.5 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 1538.56% — and 2023, when it tumbled 82.71%.
• Kymera Therapeutics' Accumulated Expenses stood at $27.5 million in 2022, then advanced by 23.13% to $33.9 million in 2023, then increased by 2.96% to $34.9 million in 2024, then rose by 21.24% to $42.3 million in 2025, then plunged by 84.1% to $6.7 million in 2026.
• Business Quant data shows KYMR's Accumulated Expenses at $6.7 million in Q1 2026, $42.3 million in Q4 2025, and $11.7 million in Q3 2025.